BIOMAT Database Logo BIOMAT Database Logo

Treatment of aggressive non-Hodgkin's lymphomas. 2007

E Tsartsidze, and M Betaneli, and N Sharikadze, and N Shavidze, and N Seskuria
Institute of Postgraduate Medical Education and Continuous Professional Development, Tbilisi State Medical University, Medulla-Chemotherapy and Immunotherapy Clinic Tbilisi, Georgia.

The aim of the study was to evaluate overall survival in patients with diagnosis DLBCL, comparing CHOP chemotherapy plus rituximab with CHOP alone, and standard plus intensive regimens (BEAM). Above mentioned regimens were compared in high risk patient, who were identified according to the CD10 expression with factors of IPI. 27 patients with diagnosis of diffuse large B-cell lymphomas were under observation. CD20 expression was assessed in all cases. Overall survival therapy was compared in three groups. I- primary refractory patients who undergone chemotherapy with CHOP regimen (9 patents); II - patients refractory to the standard added intensive chemotherapy regimens (BEAM) (10 patients). III - patients who were treated with combination CHOP plus rituximab (8 patients); As it shown on the figure overall survival was the highest in III group and composes 17 months, as for II and I groups overall survival was 7,4 and 8,8 months respectively. In summary based on our observations quantity of unfavorable prognostic factors may determine primary refractory patients to standard therapies and first line treatment in CD20 positive cases with CHOP plus Rituximab regimen increased overall survival from 7,4 month to 17 month (p<0,01).

UI MeSH Term Description Entries
D008228 Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. Non-Hodgkin Lymphoma,Diffuse Mixed Small and Large Cell Lymphoma,Diffuse Mixed-Cell Lymphoma,Diffuse Small Cleaved-Cell Lymphoma,Diffuse Undifferentiated Lymphoma,Lymphatic Sarcoma,Lymphoma, Atypical Diffuse Small Lymphoid,Lymphoma, Diffuse,Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic,Lymphoma, High-Grade,Lymphoma, Intermediate-Grade,Lymphoma, Low-Grade,Lymphoma, Mixed,Lymphoma, Mixed Cell, Diffuse,Lymphoma, Mixed Lymphocytic-Histiocytic,Lymphoma, Mixed Small and Large Cell, Diffuse,Lymphoma, Mixed-Cell,Lymphoma, Mixed-Cell, Diffuse,Lymphoma, Non-Hodgkin's,Lymphoma, Non-Hodgkin, Familial,Lymphoma, Non-Hodgkins,Lymphoma, Nonhodgkin's,Lymphoma, Nonhodgkins,Lymphoma, Pleomorphic,Lymphoma, Small Cleaved Cell, Diffuse,Lymphoma, Small Cleaved-Cell, Diffuse,Lymphoma, Small Non-Cleaved-Cell,Lymphoma, Small Noncleaved-Cell,Lymphoma, Small and Large Cleaved-Cell, Diffuse,Lymphoma, Undifferentiated,Lymphoma, Undifferentiated, Diffuse,Lymphosarcoma,Mixed Small and Large Cell Lymphoma, Diffuse,Mixed-Cell Lymphoma,Mixed-Cell Lymphoma, Diffuse,Non-Hodgkin's Lymphoma,Reticulosarcoma,Reticulum Cell Sarcoma,Reticulum-Cell Sarcoma,Sarcoma, Lymphatic,Sarcoma, Reticulum-Cell,Small Cleaved-Cell Lymphoma, Diffuse,Small Non-Cleaved-Cell Lymphoma,Small Noncleaved-Cell Lymphoma,Undifferentiated Lymphoma,Diffuse Lymphoma,Diffuse Lymphomas,Diffuse Mixed Cell Lymphoma,Diffuse Mixed-Cell Lymphomas,Diffuse Small Cleaved Cell Lymphoma,Diffuse Undifferentiated Lymphomas,High-Grade Lymphoma,High-Grade Lymphomas,Intermediate-Grade Lymphoma,Intermediate-Grade Lymphomas,Low-Grade Lymphoma,Low-Grade Lymphomas,Lymphatic Sarcomas,Lymphocytic-Histiocytic Lymphoma, Mixed,Lymphocytic-Histiocytic Lymphomas, Mixed,Lymphoma, Diffuse Mixed-Cell,Lymphoma, Diffuse Undifferentiated,Lymphoma, High Grade,Lymphoma, Intermediate Grade,Lymphoma, Low Grade,Lymphoma, Mixed Cell,Lymphoma, Mixed Lymphocytic Histiocytic,Lymphoma, Non Hodgkin,Lymphoma, Non Hodgkin's,Lymphoma, Non Hodgkins,Lymphoma, Nonhodgkin,Lymphoma, Small Non Cleaved Cell,Lymphoma, Small Noncleaved Cell,Lymphosarcomas,Mixed Cell Lymphoma,Mixed Cell Lymphoma, Diffuse,Mixed Lymphocytic-Histiocytic Lymphoma,Mixed Lymphocytic-Histiocytic Lymphomas,Mixed Lymphoma,Mixed Lymphomas,Mixed-Cell Lymphomas,Non Hodgkin Lymphoma,Non Hodgkin's Lymphoma,Non-Cleaved-Cell Lymphoma, Small,Non-Hodgkins Lymphoma,Noncleaved-Cell Lymphoma, Small,Nonhodgkin's Lymphoma,Nonhodgkins Lymphoma,Pleomorphic Lymphoma,Pleomorphic Lymphomas,Reticulosarcomas,Reticulum Cell Sarcomas,Reticulum-Cell Sarcomas,Sarcoma, Reticulum Cell,Small Cleaved Cell Lymphoma, Diffuse,Small Non Cleaved Cell Lymphoma,Small Non-Cleaved-Cell Lymphomas,Small Noncleaved Cell Lymphoma,Small Noncleaved-Cell Lymphomas,Undifferentiated Lymphoma, Diffuse,Undifferentiated Lymphomas
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D018450 Disease Progression The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis. Clinical Course,Clinical Progression,Disease Exacerbation,Exacerbation, Disease,Progression, Clinical,Progression, Disease

Related Publications

E Tsartsidze, and M Betaneli, and N Sharikadze, and N Shavidze, and N Seskuria
[Treatment of aggressive non-Hodgkin's lymphomas].
May 1998, Medicina clinica,
E Tsartsidze, and M Betaneli, and N Sharikadze, and N Shavidze, and N Seskuria
[Treatment of aggressive non-Hodgkin's lymphomas].
February 2009, Revista clinica espanola,
E Tsartsidze, and M Betaneli, and N Sharikadze, and N Shavidze, and N Seskuria
Chemotherapy of non-Hodgkin's aggressive lymphomas.
January 1994, Seminars in hematology,
E Tsartsidze, and M Betaneli, and N Sharikadze, and N Shavidze, and N Seskuria
Management of histologically aggressive non-Hodgkin's lymphomas.
April 1994, British journal of haematology,
E Tsartsidze, and M Betaneli, and N Sharikadze, and N Shavidze, and N Seskuria
Prognostic Factors in Aggressive Non-Hodgkin's Lymphomas.
January 1998, The oncologist,
E Tsartsidze, and M Betaneli, and N Sharikadze, and N Shavidze, and N Seskuria
Diffuse aggressive lymphomas: a curable subset of non-Hodgkin's lymphomas.
December 1986, Seminars in oncology,
E Tsartsidze, and M Betaneli, and N Sharikadze, and N Shavidze, and N Seskuria
EMOP/CA chemotherapy for the treatment of aggressive non-Hodgkin's lymphomas.
June 1989, European journal of cancer & clinical oncology,
E Tsartsidze, and M Betaneli, and N Sharikadze, and N Shavidze, and N Seskuria
Expression of p53 predicts treatment failure in aggressive non-Hodgkin's lymphomas.
March 1998, Leukemia & lymphoma,
E Tsartsidze, and M Betaneli, and N Sharikadze, and N Shavidze, and N Seskuria
The management of adult aggressive non-Hodgkin's lymphomas.
July 2000, Critical reviews in oncology/hematology,
E Tsartsidze, and M Betaneli, and N Sharikadze, and N Shavidze, and N Seskuria
Aggressive non-Hodgkin's lymphomas in immunocompromised homosexual males.
September 1985, Blood,
Copied contents to your clipboard!